FDA pushes back PDUFA date for Daiichi's AML drug quizartinib over REMS updates
Daiichi Sankyo said the FDA needs more time to review the NDA for its FLT3 drug quizartinib, extending the PDUFA date by three months until …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
